DURECT Corporation has announced its financial results for the first quarter of 2025. The company reported total revenues of $0.3 million for the three months ended March 31, 2025, a decline from the $0.5 million reported for the same period in 2024. The net loss for the first quarter of 2025 was $4.2 million, an improvement from the $7.6 million net loss reported for the first quarter of 2024. As of March 31, 2025, DURECT's cash, cash equivalents, and investments stood at $8.4 million, compared to $12.0 million as of December 31, 2024. In addition to financial results, DURECT provided a business update. The company is planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH), with topline results expected within two years of trial initiation. DURECT is actively exploring funding options for the continued development of larsucosterol. Furthermore, results from the AHFIRM Phase 2b trial were published in NEJM Evidence in January 2025, highlighting the potential value of larsucosterol as a treatment for AH. Additionally, on May 6, 2025, Innocoll Pharmaceuticals Limited transferred all data and know-how related to POSIMIR to DURECT following the termination of their licensing agreement. DURECT is evaluating options to find a new partner to commercialize POSIMIR.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.